Stay updated with breaking news from Robert Wenham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ...
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10
Postmenopausal women report more significant improvements in chronic pain after procedural interventions when compared with their younger counterparts, despite being notably less likely to use muscle relaxants, TCAs, and benzodiazepines.
- With no dose-limiting toxicities observed, treatment of second dose cohort to begin SAN JOSE, Calif., Oct. 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. , a biotechnology company focused on...
SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. , a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone,... -Today at 08:31 am- MarketScreener